American Association for Cancer Research

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Reuter
    Reuter
  3. Voss
    Voss
  4. Hakimi
    Hakimi
  5. Russo
    Russo
  6. Bosl
    Bosl
  7. Chaganti
    Chaganti
  8. Chen
    Chen
  9. Carlo
    Carlo
  10. Kotecha
    Kotecha

Groups

  1. Department of Medicine (46)
  2. Genitourinary Oncology Service (46)
  3. Solid Tumor Oncology Division (46)
  4. Department of Pathology and Laboratory Medicine (12)
  5. Sloan Kettering Institute Postdocs (9)
  6. Surgery (9)
  7. Survivorship Research (9)
  8. Urology (9)
  9. Epidemiology and Biostatistics (8)
  10. Human Oncology and Pathogenesis Program (8)
Search Within
  1. "Robert Motzer"
Formats
  1. Journal Article (37)
  2. Meeting Abstract (9)
Groups
  1. Department of Medicine (46)
  2. Genitourinary Oncology Service (46)
  3. Solid Tumor Oncology Division (46)
  4. Department of Pathology and Laboratory Medicine (12)
  5. Sloan Kettering Institute Postdocs (9)
  6. Surgery (9)

More Groups

People
  1. Robert Motzer (46)
  2. Martin Voss (10)
  3. Victor Reuter (10)
  4. Abraham Hakimi (8)
  5. Paul Russo (7)
  6. Chung-Han Lee (6)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (3)
  4. 2021 (7)
  5. 2020 (3)
  6. 2019 (4)

More Years

Publications
  1. Clinical Cancer Research (33)
  2. Cancer Research (13)

Results (46)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from anti-PD-1 therapy in metastatic clear-cell renal cell carcinoma patients
    Journal Article

    Denize, T.; Jegede, O. A.; Matar, S.; Al Ahmar, N.; West, D. J.; Walton, E.; Bagheri, A. S.; Savla, V.; Laimon, Y. N.; Gupta, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Jacobi, R.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade
    Journal Article

    Ged, Y.; Sanchez, A.; Patil, S.; Knezevic, A.; Stein, E.; Petruzella, S.; Weiss, K.; Duzgol, C.; Chaim, J.; Akin, O.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma
    Journal Article

    Denize, T.; Hou, Y.; Pignon, J. C.; Walton, E.; West, D. J.; Freeman, G. J.; Braun, D. A.; Wu, C. J.; Gupta, S.; Motzer, R. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial
    Journal Article

    Regan, M. M.; Jegede, O. A.; Mantia, C. M.; Powles, T.; Werner, L.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Prevalence and landscape of actionable genomic alterations in renal cell carcinoma
    Journal Article

    Attalla, K.; DiNatale, R. G.; Rappold, P. M.; Fong, C. J.; Sanchez-Vega, F.; Silagy, A. W.; Weng, S.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • IMmotion151: Updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Rini, B. I.; Atkins, M. B.; Escudier, B.; Powles, T.; McDermott, D. F.; Alekseev, B. Y.; Lee, J. L.; Stroyakovskiy, D.; Suarez Rodriguez, C.; De Giorgi, U.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors
    Meeting Abstract

    Hammers, H.; Choueiri, T.; Plimack, E.; Rini, B.; Motzer, R.; Yin, L.; Perini, R.; Willemann-Rogerio, J.; Albiges, L.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma
    Journal Article

    Gleeson, J. P.; Nikolovski, I.; Dinatale, R.; Zucker, M.; Knezevic, A.; Patil, S.; Ged, Y.; Kotecha, R. R.; Shapnik, N.; Murray, S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: